Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 936063, 8 pages
http://dx.doi.org/10.1155/2013/936063
Clinical Study

Immune Response following Liver Transplantation Compared to Kidney Transplantation: Usefulness of Monitoring Peripheral Blood CD4+ Adenosine Triphosphate Activity and Cytochrome P450 3A5 Genotype Assay

1Department of Hepatobiliary Pancreatic and Transplant Surgery, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan
2Divisions of Nephro-Urologic Surgery and Andrology, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan
3Department of Molecular and Laboratory Medicine, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan
4Department of Pharmacy, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan
5Translational Medical Science, Mie University School of Medicine, 2-174 Edobashi, Tsu, Mie 514-0001, Japan

Received 9 September 2013; Revised 26 November 2013; Accepted 1 December 2013

Academic Editor: Basak Kayhan

Copyright © 2013 Yu Nobuoka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Brick, O. Atouf, N. Benseffaj, and M. Essakalli, “Rejection of kidney graft: mechanism and prevention,” Nephrologie et Therapeutique, vol. 7, no. 1, pp. 18–26, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. A. E. Grulich, M. T. van Leeuwen, M. O. Falster, and C. M. Vajdic, “Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis,” The Lancet, vol. 370, no. 9581, pp. 59–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. R. Shapiro, “End-stage renal disease in 2010: innovative approaches to improve outcomes in transplantation,” Nature Reviews Nephrology, vol. 7, no. 2, pp. 68–70, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. R. Venkataramanan, L. M. Shaw, L. Sarkozi et al., “Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients,” Journal of Clinical Pharmacology, vol. 41, no. 5, pp. 542–551, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group, “KDIGO clinical practice guideline for the care of kidney transplant recipients,” American Journal of Transplantation, vol. 9, supplement 3, pp. S1–S155, 2009. View at Publisher · View at Google Scholar
  6. R. J. Kowalski, D. R. Post, R. B. Mannon et al., “Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay,” Transplantation, vol. 82, no. 5, pp. 663–668, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Gautam, S. A. Fischer, A. F. Yango, R. Y. Gohh, P. E. Morrissey, and A. P. Monaco, “Cell mediated immunity (CMI) and post transplant viral infections—Role of a functional immune assay to titrate immunosuppression,” International Immunopharmacology, vol. 6, no. 13-14, pp. 2023–2026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Huskey, J. Gralla, and A. C. Wiseman, “Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 2, pp. 423–429, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Torío, E. J. Fernández, O. Montes-Ares, R. M. Guerra, M. A. Pérez, and M. D. Checa, “Lack of association of immune cell function test with rejection in kidney transplantation,” Transplantation Proceedings, vol. 43, no. 6, pp. 2168–2170, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Shiraga, H. Matsuda, K. Nagase et al., “Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes,” Biochemical Pharmacology, vol. 47, no. 4, pp. 727–735, 1994. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Fukudo, I. Yano, A. Yoshimura et al., “Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients,” Pharmacogenetics and Genomics, vol. 18, no. 5, pp. 413–423, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Durand, D. Debray, M. Kolaci et al., “Tacrolimus dose requirement in pediatric liver transplantation: influence of CYP3A5 gene polymorphism,” Pharmacogenomics, vol. 14, no. 9, pp. 1017–1025, 2013. View at Google Scholar
  13. V. Haufroid, M. Mourad, V. Van Kerckhove et al., “The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients,” Pharmacogenetics, vol. 14, no. 3, pp. 147–154, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. X. Zhang, Z.-H. Liu, J.-M. Zheng et al., “Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation,” Clinical Transplantation, vol. 19, no. 5, pp. 638–643, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Demetris, K. P. Batts, A. P. Dhillon et al., “Banff schema for grading liver allograft rejection: an international consensus document,” Hepatology, vol. 25, no. 3, pp. 658–663, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Mizuno, T. Hamada, K. Nakatani et al., “Monitoring peripheral blood CD4+ adenosine triphosphate activity after living donor liver transplantation: impact of combination assays of immune function and CYP3A5 genotype,” Journal of Hepato-Biliary-Pancreatic Sciences, vol. 18, no. 2, pp. 226–234, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Fukuen, T. Fukuda, H. Maune et al., “Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population,” Pharmacogenetics, vol. 12, no. 4, pp. 331–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. J. A. Fishman, “Infection in solid-organ transplant recipients,” The New England Journal of Medicine, vol. 357, no. 25, pp. 2601–2614, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Rodrigo, M. López-Hoyos, M. Corral et al., “ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: a systematic review and meta-analysis,” Liver Transplantation, vol. 18, no. 10, pp. 1245–1253, 2012. View at Google Scholar
  20. X. Ling, J. Xiong, W. Liang et al., “Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis,” Transplantation, vol. 93, no. 7, pp. 737–743, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Muraki, M. Usui, S. Isaji et al., “Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients,” Annals of Transplantation, vol. 16, no. 4, pp. 55–62, 2011. View at Google Scholar · View at Scopus